Clinical Trial

A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma

Study acronym: DARVIVA
Unknown Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2024 (before its estimated January 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to confirm the comparability of the efficacy and safety profiles of BCD-264 and Darzalex as monotherapy for relapsed and refractory multiple myeloma in subjects previously treated with proteasome inhibitors and immunomodulatory drugs, and who had disease progression on prior therapy.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT06296121
Lead Sponsor Biocad
Conditions Multiple Myeloma
Enrollment 252 participants
Start Date 2023-12-21
Primary Completion 2025-01 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2024-03-06